-
Search IP Databases
- CIOPORA Copyright EPO EU EUIPO European Commission European Patent Office European Union Federal Circuit Goods and Services Industrial Designs Infringement innovation intellectual property Intellectual Property Rights International Registration invention IP Madrid Protocol Maier and Maier OHIM patent patents PCT trade mark trademark Trademarks USPTO WIPO World Intellectual Property Organization
- view all tags
IP4all Weekly Bulletin
-
-
-
-
-
-
-
-
IP Basis®
IP Guide®
Archive: 30 Sep 2011
Лек против пушење кој е надвор од патентна заштита претставува закана за Pfizer
Pfizer се соочува со закана во продажбата на лекот Campix,која доаѓа од страна на бугарска компанија, заради пласманот на лек кој припаѓа на нерегистираниот генерички пазар. Во една клиничка студија финансирана од страна на британски добротворни организации и медицински агенции за финансирање,добиени се ветувачки резултати во третманот со Tabex,лек продаван од страна на Софарма, со […]
Pfizer faces off-patent smoking drug threat
Pfizer is facing a threat to its top-selling smoking cessation drug Champix from the Bulgarian company that has long marketed the low-cost off-patent medicine from which it was derived. A clinical study financed by British charities and medical funding agencies concludes that Tabex, sold by Sofia-based Sopharma, is promising because it is as effective and […]
Pfizer faces off-patent smoking drug threat
Pfizer is facing a threat to its top-selling smoking cessation drug Champix from the Bulgarian company that has long marketed the low-cost off-patent medicine from which it was derived. A clinical study financed by British charities and medical funding agencies concludes that Tabex, sold by Sofia-based Sopharma, is promising because it is as effective and […]
Pfizer is facing a threat to its top-selling smoking cessation drug Champix from the Bulgarian company that has long marketed the low-cost off-patent medicine from which it was derived. A clinical study financed by British charities and medical funding agencies concludes that Tabex, sold by Sofia-based Sopharma, is promising because it is as effective and […]